| 11-FMHP_PRV_23.80_164_S_Carta-Tramite-Carta-Normativa-23-0927-1-ingles.pdf |
2023/09/27 |
|
| 22-0929-Aclaracion-Proceso-de-pago-Vital-ing.pdf |
2022/09/29 |
|
| Access-to-Protected-Health-Information-PHI-Form.pdf |
|
|
| Asthma-Management-Program-2021.pdf |
2021/01/01 |
|
| Binder2.pdf |
|
|
| CARTA-CIRCULAR-20-0930-ACLARATORIA-SOBRE-COPAGOS-Y-DEDUCIBLES-PARA-LOS-PROCEDIMIENTOS-DE-LABORATORIOS-PARA-LA-DETECCIÓN-DEL-COVID-19_PRUEBA-RÁP.pdf |
2020/09/30 |
|
| CN-22-0928-ing.pdf |
2022/09/28 |
|
| CN-22-0929-ing.pdf |
2022/09/29 |
|
| Carta-Circular-19-0530-Educacion-Manejo-Genericos-Autorizados-merge.pdf |
2019/05/30 |
|
| Carta-Circular-20-0421-merge.pdf |
2020/04/21 |
|
| Carta-Circular-20-0423-TeleHealth-Terapia-Fisica-y-Ocupacional-merge.pdf |
2020/04/23 |
|
| Carta-Circular-20-0603-01-Registro-de-recién-nacidos-al-portal-de-Medicaid-merge.pdf |
2020/06/03 |
|
| Carta-Circular-20-0612-relacionada-al-Retiro-de-Algunos-Lotes-de-Metformin-merge.pdf |
2020/06/12 |
|
| Carta-Circular-20-0619-merge.pdf |
2020/06/19 |
|
| Carta-Circular-20-0630-relacionada-a-la-Actualización-del-Manejo-de-Cloroquina-merge.pdf |
2020/06/30 |
|
| Carta-Circular-20-0713-relacionada-a-Aclaratoria-de-Cartas-Normativas-20-0331-02-merge.pdf |
2020/07/13 |
|
| Carta-Circular-20-0806-relacionada-a-la-Transición-de-Pacientes-de-Molina-Healthcare-merge.pdf |
2020/08/06 |
|
| Carta-Circular-20-1015-relacionada-a-la-Eliminación-de-Restricción-por-Género-en-los-Formularios-de-Medicamentos-del-Plan-Vital-merge-1.pdf |
2020/10/15 |
|
| Carta-Circular-Cierre-de-Farmacias-Kmart-10.25.2019-m.pdf |
2019/01/01 |
|
| Carta-Informativa-Programa-de-Asma-merge.pdf |
|
|
| Carta-Informativa-Servicios-Dentales-Plan-Vital.pdf |
|
|
| Carta-Informativa-para-la-Red-de-Proveedores-General-relacionada-al-Plan-Vital.pdf |
|
|
| Carta-Normatiuva-20-0713-01Cierre-Farmacias-KMART-merge.pdf |
2020/07/13 |
|
| Carta-Normativa-15-002-Cubierta-Anticonceptivos.pdf |
|
|
| Carta-Normativa-18-10-02.pdf |
2018/10/02 |
|
| Carta-Normativa-18-1102-Cambios-al-Formulario-de-Cubierta.pdf |
2018/11/02 |
|
| Carta-Normativa-19-0116-Enmendada.pdf |
2019/01/16 |
|
| Carta-Normativa-19-0130-de-la-Administración-de-Seguros-de-Salud-de-Puerto-Rico-Merge.pdf |
2019/01/30 |
|
| Carta-Normativa-19-0305-merge.pdf |
2019/03/05 |
|
| Carta-Normativa-19-0319 (1).pdf |
2019/03/19 |
|
| Carta-Normativa-19-0319.pdf |
2019/03/19 |
|
| Carta-Normativa-19-0627-relacionada-a-la-Cubierta-de-Suboxone®-SL-FILM-presentación-merge.pdf |
2019/06/27 |
|
| Carta-Normativa-19-0826-Enmendada-merge.pdf |
2019/08/26 |
|
| Carta-Normativa-19-0826A-FMC-Enmendada-merge.pdf |
2019/08/26 |
|
| Carta-Normativa-19-0904-Cambios-en-la-Cubierta-de-Albuterol-merge.pdf |
2019/09/04 |
|
| Carta-Normativa-19-0919-Interferon-Gamma-Release-Assays-IGRAs-merge.pdf |
2019/09/19 |
|
| Carta-Normativa-19-1023-Cambio-en-el-édito-de-suplidos-para-las-bombas-de-infusión-de-insulina-m.pdf |
2019/10/23 |
|
| Carta-Normativa-19-1104-Formulario-de-Referido-y-o-Consulta-y-Formulario-de-Preautorizaciones-del-Plan-Vital-m.pdf |
2019/11/04 |
|
| Carta-Normativa-20-03-16A-m.pdf |
2020/03/16 |
|
| Carta-Normativa-20-03-16B-Enmendada-merge.pdf |
2020/03/16 |
|
| Carta-Normativa-20-03-16B-m.pdf |
2020/03/16 |
|
| Carta-Normativa-20-03-18-Enmendada-merge.pdf |
2020/03/18 |
|
| Carta-Normativa-20-0311-COVID-19-m.pdf |
2020/03/11 |
|
| Carta-Normativa-20-0317-de-la-Administración-de-Seguros-de-Salud-de-Puerto-Rico-m.pdf |
2020/03/17 |
|
| Carta-Normativa-20-0320-de-la-Administración-de-Seguros-de-Salud-de-Puerto-Rico-merge.pdf |
2020/03/20 |
|
| Carta-Normativa-20-0326-referente-a-Inclusión-de-Maviret®-m.pdf |
2020/03/26 |
|
| Carta-Normativa-20-04-01A-merge.pdf |
2020/04/01 |
|
| Carta-Normativa-20-0402A-Teledentistry-merge.pdf |
2020/04/02 |
|
| Carta-Normativa-20-0427-merge.pdf |
2020/04/27 |
|
| Carta-Normativa-20-05-01-relacionada-al-Código-para-la-Cubierta-Dental-merge.pdf |
2020/05/01 |
|
| Carta-Normativa-20-05-01A-Código-para-la-Cubierta-Dental-merge.pdf |
2020/05/01 |
|
| Carta-Normativa-20-0514-de-la-Administración-de-Seguros-de-Salud-de-Puerto-Rico-merge-1.pdf |
2020/05/14 |
|
| Carta-Normativa-20-0527-relacionada-a-la-Efectividad-de-la-Medida-de-Sustentabilidad-merge.pdf |
2020/05/27 |
|
| Carta-Normativa-20-0529-relacionada-a-Cambios-en-el-Formulario-de-Medicamentos-merge-1.pdf |
2020/05/29 |
|
| Carta-Normativa-20-0611-relacionada-a-Medicamentos-Anticonvulsivos-merge.pdf |
2020/06/11 |
|
| Carta-Normativa-20-0616-01-merge.pdf |
2020/06/16 |
|
| Carta-Normativa-20-0717-Suspensión-del-Requerimiento-de-Referidos.pdf |
2020/07/17 |
|
| Carta-Normativa-20-0824-Descontinuación-de-la-venta-y-distribución-de-Coumadin®-warfarina-sódica-tabletas-merge.pdf |
2020/08/24 |
|
| Carta-Normativa-20-0825-relacionada-al-Ajuste-en-el-Suplido-de-Cantidad-Mensual-de-de-Lantus-merge.pdf |
2020/08/25 |
|
| Carta-Normativa-2019-0320.pdf |
2019/03/20 |
|
| Carta-Normativa-22-1031-1-ing.pdf |
2022/10/31 |
|
| Carta-Normativa-Cambio-en-Cubierta-de-Suboxone®-SL-FILM.pdf |
|
|
| Carta-Normativa-Cambios-Beneficio-de-Cubierta-2019.pdf |
2019/01/01 |
|
| Carta-Normativa-Cambios-al-Formulario-de-Medicamentos-en-Cubierta_Spanish-m.pdf |
|
|
| Carta-Normativa-Cubierta-de-Anticonceptivos-Edad-Reproductiva.pdf |
|
|
| Carta-Normativa-Fomulario-Pre-Autorización-Merge.pdf |
|
|
| Carta-Normativa-Naxolona.pdf |
|
|
| Carta-Normativa-Número-18-0705-A.pdf |
2018/07/05 |
|
| Carta-Normativa-Registro-Medicos-Merge-1.pdf |
|
|
| Carta-Normativa-Segunda-Extension-Transicion-Vital.pdf |
|
|
| Carta-Normativa-relacionada-a-la-Cubierta-y-Beneficios-para-COVID-19-merge.pdf |
|
|
| Carta-Normativas-19-1022-Política-de-ASES-sobre-cernimiento-y-diagnóstico-de-pérdida-de-audición_editada-m.pdf |
2019/10/22 |
|
| Carta-Tramite-Carta-Normativa-18-1116-def.pdf |
2018/11/16 |
|
| Carta-Tramite-Carta-Normativa-23-0606-2.pdf |
2023/06/06 |
|
| Carta-Tramite-Orientacion-Proveedores-FM-Vital.pdf |
|
|
| Carta-Tramite-y-Normativa-18-1116-11212018.pdf |
2018/11/16 |
|
| Carta5OctEnmendada.pdf |
|
|
| CartaModeloIntegracionSaludFisicaMental.pdf |
|
|
| CartaNormativa181003Enmendada (1).pdf |
2018/10/03 |
|
| CartaPeriodoTranssicionPlanVital.pdf |
|
|
| CertificadoExamenOral.pdf |
|
|
| Circular-Letter-18-0813-A-Notificación-sobre-cambio-en-Formulario-para-Medicamentos-J-Codes.pdf |
2018/08/13 |
|
| Circular-Letter-2022-001.pdf |
2022/01/01 |
|
| Circular-Letter-22-0125.pdf |
2022/01/25 |
|
| Circular-Letter-23-0908-01.pdf |
2023/09/08 |
|
| Circular-Letter-23-0908.pdf |
2023/09/08 |
|
| Circular-Letter-23-1221.pdf |
2023/12/21 |
|
| Circular-letter-20-0402.pdf |
2020/04/02 |
|
| Clinical-Practice-Guidelines-2021.pdf |
2021/01/01 |
|
| Communication-regarding-Administrative-Order-No.-2021-507.pdf |
|
|
| Communication-regarding-Administrative-Order-No.-460.pdf |
2021/01/01 |
|
| Communication-regarding-Administrative-Order-No.-476.pdf |
|
|
| Communication-regarding-Circular-Letter-20-1020-01.pdf |
2020/10/20 |
|
| Communication-regarding-Circular-Letter-20-1020.pdf |
2020/10/20 |
|
| Communication-regarding-Circular-Letter-20-1028-01.pdf |
2020/10/28 |
|
| Communication-regarding-Circular-Letter-20-1028.pdf |
2020/10/28 |
|
| Communication-regarding-Circular-Letter-20-1106.pdf |
2020/11/06 |
|
| Communication-regarding-Circular-Letter-20-1217.pdf |
2020/12/17 |
|
| Communication-regarding-Circular-Letter-No.-21-0104.pdf |
2021/01/04 |
|
| Communication-regarding-Circular-Letter-No.-21-0114-1.pdf |
2021/01/14 |
|
| Communication-regarding-Circular-Letter-No.-21-0114.pdf |
2021/01/14 |
|
| Communication-regarding-Circular-Letter-No.-21-0324.pdf |
2021/03/24 |
|
| Communication-regarding-Extension-of-Eligibility-COVID-19.pdf |
|
|
| Communication-regarding-Informative-Letter-related-to-the-Obligation-and-Responsibility-to-Provide-Medical-Services-to-Citizens.pdf |
|
|
| Communication-regarding-Normative-Letter-20-0304-related-to-Autism-Provisional-Special-Coverage.pdf |
2020/03/04 |
|
| Communication-regarding-Normative-Letter-20-1008.pdf |
2020/10/08 |
|
| Communication-regarding-Normative-Letter-20-1023-01A.pdf |
2020/10/23 |
|
| Communication-regarding-Normative-Letter-20-1023-01B.pdf |
2020/10/23 |
|
| Communication-regarding-Normative-Letter-20-1023-merge.pdf |
2020/10/23 |
|
| Communication-regarding-Normative-Letter-20-1030.pdf |
2020/10/30 |
|
| Communication-regarding-Normative-Letter-20-1106A.pdf |
2020/11/06 |
|
| Communication-regarding-Normative-Letter-20-1210 (1).pdf |
2020/12/10 |
|
| Communication-regarding-Normative-Letter-20-1210.pdf |
2020/12/10 |
|
| Communication-regarding-Normative-Letter-20-1214-D.pdf |
2020/12/14 |
|
| Communication-regarding-Normative-Letter-20-1214-F.pdf |
2020/12/14 |
|
| Communication-regarding-Normative-Letter-20-1214.pdf |
2020/12/14 |
|
| Communication-regarding-Normative-Letter-20-1217.pdf |
2020/12/17 |
|
| Communication-regarding-Normative-Letter-21-0603.pdf |
2021/06/03 |
|
| Communication-regarding-Normative-Letter-21-0817.pdf |
2021/08/17 |
|
| Communication-regarding-Normative-Letter-21-0921.pdf |
2021/09/21 |
|
| Communication-regarding-Normative-Letter-21-0923.pdf |
2021/09/23 |
|
| Communication-regarding-Normative-Letter-22-0127.pdf |
2022/01/27 |
|
| Communication-regarding-Normative-Letter-22-0202.pdf |
2022/02/02 |
|
| Communication-regarding-Normative-Letter-22-0209.pdf |
2022/02/09 |
|
| Communication-regarding-Normative-Letter-22-0303.pdf |
2022/03/03 |
|
| Communication-regarding-Normative-Letter-22-0308.pdf |
2022/03/08 |
|
| Communication-regarding-Normative-Letter-Amendment-22-0208.pdf |
2022/02/08 |
|
| Communication-regarding-Normative-Letter-No-21-0223.pdf |
2021/02/23 |
|
| Communication-regarding-Normative-Letter-No.-20-1023-01.pdf |
2020/10/23 |
|
| Communication-regarding-Normative-Letter-No.-20-1023-01C.pdf |
2020/10/23 |
|
| Communication-regarding-Normative-Letter-No.-20-1110-A.pdf |
2020/11/10 |
|
| Communication-regarding-Normative-Letter-No.-20-1210.pdf |
2020/12/10 |
|
| Communication-regarding-Normative-Letter-No.-20-1214B.pdf |
2020/12/14 |
|
| Communication-regarding-Normative-Letter-No.-20-1214C.pdf |
2020/12/14 |
|
| Communication-regarding-Normative-Letter-No.-21-0104.pdf |
2021/01/04 |
|
| Communication-regarding-Normative-Letter-No.-21-0121.pdf |
2021/01/21 |
|
| Communication-regarding-Normative-Letter-No.-21-0129.pdf |
2021/01/29 |
|
| Communication-regarding-Normative-Letter-No.-21-0211-A.pdf |
2021/02/11 |
|
| Communication-regarding-Normative-Letter-No.-21-0211.pdf |
2021/02/11 |
|
| Communication-regarding-Normative-Letter-No.-21-0305A.pdf |
2021/03/05 |
|
| Communication-regarding-Normative-Letter-No.-21-0308.pdf |
2021/03/08 |
|
| Communication-regarding-Normative-Letter-No.-21-0414-.pdf |
2021/04/14 |
|
| Communication-regarding-Normative-Letter-No.-21-0505.pdf |
2021/05/05 |
|
| Communication-regarding-Normative-Letter-No.-21-0708.pdf |
2021/07/08 |
|
| Communication-regarding-Normative-Letter-No.-21-0712.pdf |
2021/07/12 |
|
| Communication-regarding-Normative-Letter-No.-21-1005.pdf |
2021/10/05 |
|
| Communication-regarding-Normative-Letter-Number-19-0726-related-to-Vaccination.pdf |
2019/07/26 |
|
| Communication-regarding-Normative-Letter-Number-20-1110-Billing-for-Remdesivir-Plasma-Convalescent-Services-Treatments.pdf |
2020/11/10 |
|
| Communication-regarding-Normative-Letter21-0517.pdf |
2021/05/17 |
|
| Communication-regarding-Normative-Letter21-0528.pdf |
2021/05/28 |
|
| Communication-regarding-Transmittal-Letter-Deadline-related-to-Provider-Enrollment-Portal.pdf |
|
|
| Communication-regarding-the-Eligibility-Extension-COVID-19.pdf |
|
|
| Communication-regarding-the-Special-Enrollment-Period-1.pdf |
|
|
| Communication-regarding-to-the-Letter-for-Healthcare-Providers-Línea-de-Cesación-de-Fumar-¡Déjalo-Ya.pdf |
|
|
| Comunicado-Tormenta-Karen-Cumplimiento.pdf |
|
|
| Comunicado-referente-a-la-Carta-Circular-20-1112-relacionada-a-Aclaratoria-Restablecimiento-del-Requisito-de-Referido.pdf |
2020/11/12 |
|
| Comunicado-referente-a-la-Carta-Normativa-2019-10-2-Tarifario-Dental.pdf |
2019/10/01 |
|
| DSPR_Carta-Tramite-Carta-Circular-23-02.pdf |
2023/02/01 |
|
| Directorio-First-Medical-ASES-EN-2020-10-06-Formato-ASES-en-Ingles-final.pdf |
2020/10/06 |
|
| FMHP-Preventive-Care-Services-Guideline-2019.pdf |
2019/01/01 |
|
| FMHP-Preventive-Care-Services-Guidelines-2021 (1).pdf |
2021/01/01 |
|
| FMHP-Preventive-Care-Services-Guidelines-2021.pdf |
2021/01/01 |
|
| FMHP_P-2.pdf |
|
|
| FMHP_PRV_19.80_01_S-Carta-Informativa-Población-Vital-X_Spanish-Approved-03192019.pdf |
2019/01/01 |
|
| FMHP_PRV_19.80_114_S-Carta-Informativa-Diabetes-Ley-Núm.-177-del-año-2016_Spanish-Approved-10092019-m.pdf |
2019/01/01 |
|
| FMHP_PRV_19.80_121_S-Carta-Informativa-Cubierta-Especial-de-Autismo_Spanish-Approved-10252019-m.pdf |
2019/01/01 |
|
| FMHP_PRV_19.80_139_S-Carta-Trámite-Cierre-de-Farmacias-Kmart_Spanish-Approved-12192019-m.pdf |
2019/01/01 |
|
| FMHP_PRV_19.80_48_E-Clinical-Practice-Guidelines-Notification_English-A....pdf |
2019/01/01 |
|
| FMHP_PRV_19.80_48_E-Clinical-Practice-Guidelines-Notification_English-Approved-05082019.pdf |
2019/01/01 |
|
| FMHP_PRV_19.80_80_S-Carta-Trámite-Carta-Normativa-19-0724A_Spanish-Approved-07262019-Merge.pdf |
2019/07/24 |
|
| FMHP_PRV_20.80_06_E-Transmittal-Letter-related-to-Provider-Enrollment-Portal_English-Approved-01142020-m.pdf |
2020/01/01 |
|
| FMHP_PRV_20.80_123_S-Plan-Vital_Carta-Trámite-Carta-Normativa-20-0819-relacionada-al-Requisito-de-Contrafirma_Spanish-merge.pdf |
2020/08/19 |
|
| FMHP_PRV_20.80_128_E-Plan-Vital_Transmittal-Letter-Circular-Letter-20-0826-02_English-Approved-08282020-merge.pdf |
2020/08/26 |
|
| FMHP_PRV_20.80_17_S-Carta-Trámite-Cierre-de-Farmacia-Kmart_Spanish-m.pdf |
2020/01/01 |
|
| FMHP_PRV_20.80_33_S-Carta-Trámite-Carta-Normativa-20-0318-A_Spanish-Approved-m.pdf |
2020/03/18 |
|
| FMHP_PRV_20.80_56_S-Carta-Trámite-Carta-Normativa-20-04-20-Disponibilidad-de-la-Red-de-Dentistas_Spanish-Approved-04212020-merge.pdf |
2020/04/20 |
|
| FMHP_PRV_20.80_58_S-Carta-Informativa-Orden-Administrativa-Núm.-430-del-Departamento-de-Salud-de-PR_Spanish-Approved-04222020-merge.pdf |
2020/01/01 |
|
| FMHP_PRV_20.80_86_E-Plan-Vital_Clinical-Practice-Guidelines_English-Approved-06122020.pdf |
2020/01/01 |
|
| FMHP_PRV_20.80_86_S-Clinical-Practice-Guidelines_English-Approved-06122020.pdf |
2020/01/01 |
|
| FMHP_PRV_20.80_97_S-Plan-Vital_Carta-Trámite-Carta-Normativa-20-03-16A-Enmendada-relacionada-al-Restablecimiento-de-Pre-Autorizaciones-merge.pdf |
2020/03/16 |
|
| FMHP_PRV_22.80_54_E-Directorio-de-Proveedores-Inglés-mayo-2022.pdf |
2022/01/01 |
|
| FMHP_PRV_22.80_74_E_-Providers-Directory_Vital_English_Approved_08312022.pdf |
2022/01/01 |
|
| FMHP_PRV_22.80_85_E_Clinical-Practices-Guidelines_English_Approved_09122022.pdf |
2022/01/01 |
|
| FM_PRV_20.80_51_S-Carta-Trámite-Carta-Normativa-20-0404A_Enmienda-a-Carta-Normativa-20-0404-_Spanish-Aprobada-merge.pdf |
2020/04/04 |
|
| FORMULARIO_ORDEN_ADMINISTRATIVA_426_CORONAVIRUS_MUJERES_EMBARAZADAS-m-rev.pdf |
|
|
| Formulario-de-Cernimiento-de-Riesgo-de-Caries-m.pdf |
|
|
| Guias-de-Proveedores-m.pdf |
|
|
| Informative-Letter-20-0330-Pruebas-Serodiagnóticas-Determinación-Elegibilidad-Administración-Vacuna-dengue.pdf |
2020/03/30 |
|
| Informative-Letter-2022-0321-Manejo-Escasez-Medicamento-Losartan-Hidroclorotiazida-HCTZ.pdf |
2022/03/21 |
|
| Informative-Letter-21-0511A-Revisión-al-Formulario-Estándar-Registro-de-Condiciones-Especiales.pdf |
2021/05/11 |
|
| Informative-Letter-22-0202-A-Enmendada.pdf |
2022/02/02 |
|
| Informative-Letter-Administrative-Order-No.-537-Professional-Licenses-Extension-issued-by-ORCS-JLDM-until-December-31-2022.pdf |
2022/01/01 |
|
| Informative-Letter-Brief-Guide-of-monkeypox-in-P.R..pdf |
|
|
| Informative-Letter-Medicaid-Extension-of-Elegibility-until-January-2023.pdf |
2023/01/01 |
|
| Informative-Letter-Public-Notice-Plan-Vital-PBM-Change-Pharmacy-Benefit.pdf |
|
|
| Informative-letter-21-0715.pdf |
2021/07/15 |
|
| Informative-letter-Puerto-Rico-Medicaid-Program-update-information.pdf |
|
|
| Ingles.pdf |
|
|
| Letter-Provider-Enrollment-Portal-eng-m.pdf |
|
|
| Letter-of-Transmittal-Terminación-de-Emergencia-e-Inicio-Proceso-de-Recertificación-de-Medicaid.pdf |
|
|
| NC-23-1201.pdf |
2023/12/01 |
|
| Normative-Letter-20-0417.pdf |
2020/04/17 |
|
| Normative-Letter-20-1106.pdf |
2020/11/06 |
|
| Normative-Letter-2021-1028.pdf |
2021/10/28 |
|
| Normative-Letter-2022-0411-Revocación-de-Autorización-de-Uso-del-medicamento-SOTROVIMAB-en-Puerto-Rico.pdf |
2022/04/11 |
|
| Normative-Letter-21-0317-A-Prevención-de-caries-mediante-aplicación-de-Barniz-de-Fluoruro.pdf |
2021/03/17 |
|
| Normative-Letter-21-0817-A.pdf |
2021/08/17 |
|
| Normative-Letter-21-1109.pdf |
2021/11/09 |
|
| Normative-Letter-21-1214-01.pdf |
2021/12/14 |
|
| Normative-Letter-21-1214-02.pdf |
2021/12/14 |
|
| Normative-Letter-21-1214-03.pdf |
2021/12/14 |
|
| Normative-Letter-21-1214-04.pdf |
2021/12/14 |
|
| Normative-Letter-21-1223.pdf |
2021/12/23 |
|
| Normative-Letter-22-0103-1.pdf |
2022/01/03 |
|
| Normative-Letter-22-0103.pdf |
2022/01/03 |
|
| Normative-Letter-22-0127-01.pdf |
2022/01/27 |
|
| Normative-Letter-22-0128.pdf |
2022/01/28 |
|
| Normative-Letter-22-0202-B.pdf |
2022/02/02 |
|
| Normative-Letter-22-0208.pdf |
2022/02/08 |
|
| Normative-Letter-22-0628-1-1.pdf |
2022/06/28 |
|
| Normative-Letter-22-0628-1.pdf |
2022/06/28 |
|
| Normative-Letter-22-0819.pdf |
2022/08/19 |
|
| Normative-Letter-No.-20-1214B.pdf |
2020/12/14 |
|
| Normative-letter-21-1001.pdf |
2021/10/01 |
|
| Normative-letter-21-1022-.pdf |
2021/10/22 |
|
| OPP-Open-Letter-Transmittal-Letter.pdf |
|
|
| Orden-Administrativa-19-0827-B-merge.pdf |
2019/08/27 |
|
| Orden-Administrativa-19-0827-relacionada-a-la-Política-de-la-Administración-de-Servicios-merge.pdf |
2019/08/27 |
|
| Orden-Administrativa-424-merge.pdf |
|
|
| Orden-Administrativa-Núm.-442-merge.pdf |
|
|
| PRIOR-AUTHORIZATION-PROTOCOL-FOR-CANCER-TREATMENT-ANDOR-GENETICAL-STUDIES-SERVICES.pdf |
|
|
| Preventive-Services-Guidelines-2018.pdf |
2018/01/01 |
|
| Privacy-Practice-Notification-FMHP-2022_English_Approved_06062022.pdf |
2022/01/01 |
|
| Providers-Guidelines-2020.pdf |
2020/01/01 |
|
| Puerto-Rico-Medicaid-Program-Provider-Enrollment-Portal-–-Wave-5-Training-and-Enrollment-Dates-merge.pdf |
|
|
| Puerto-Rico-Medicaid-Program-Provider-Enrollment-Portal-–-Wave-7-Training-and-Enrollment-Dates-merge.pdf |
|
|
| QA-Normative-Letter-22-0330.pdf |
2022/03/30 |
|
| Questions-and-Answers-New-Poverty-Level.pdf |
|
|
| Quick-Guide-Plan-Vital-Mobile-Application.pdf |
|
|
| Recomend_AIimentación_-0-a-24-meses-merge.pdf |
2020/01/01 |
|
| Suspensión-de-las-Órdenes-Administrativas-19-0827-y-19-0827B-merge.pdf |
2019/08/27 |
|
| Teledentistry-codes-CN-2-april-2020-rev-merge-1.pdf |
2020/01/01 |
|
| Trammital-Letter-CN-2022-315-AS-Tarifa-de-las-Pruebas-para-la-Detección-del-COVID-19.pdf |
2022/01/01 |
|
| Transmittal-Letter (1).pdf |
|
|
| Transmittal-Letter (2).pdf |
|
|
| Transmittal-Letter-22-0930.pdf |
2022/09/30 |
|
| Transmittal-Letter-A.O-No.-568.pdf |
|
|
| Transmittal-Letter-A.O.-No.580.pdf |
|
|
| Transmittal-Letter-AO-22-1114.pdf |
2022/11/14 |
|
| Transmittal-Letter-AO-22-1129.pdf |
2022/11/29 |
|
| Transmittal-Letter-AO-560.pdf |
|
|
| Transmittal-Letter-AO-Num.-552.pdf |
|
|
| Transmittal-Letter-Atento-el-Departamento-de-Salud-a-viruela-del-mono-o-Monkeypox.pdf |
|
|
| Transmittal-Letter-CC-2023-002.pdf |
2023/01/01 |
|
| Transmittal-Letter-CC-23-0608.pdf |
2023/06/08 |
|
| Transmittal-Letter-CC-23-0721.pdf |
2023/07/21 |
|
| Transmittal-Letter-CL-2023-001.pdf |
2023/01/01 |
|
| Transmittal-Letter-CL-22-1021.pdf |
2022/10/21 |
|
| Transmittal-Letter-CL-23-0118-1.pdf |
2023/01/18 |
|
| Transmittal-Letter-CL-23-0403.pdf |
2023/04/03 |
|
| Transmittal-Letter-CL-23-0404-A.pdf |
2023/04/04 |
|
| Transmittal-Letter-CL-23-0404.pdf |
2023/04/04 |
|
| Transmittal-Letter-CL-23-0420.pdf |
2023/04/20 |
|
| Transmittal-Letter-CL-23-0710.pdf |
2023/07/10 |
|
| Transmittal-Letter-CL-23-0721.pdf |
2023/07/21 |
|
| Transmittal-Letter-CL-23-0807.pdf |
2023/08/07 |
|
| Transmittal-Letter-CL-23-0907.pdf |
2023/09/07 |
|
| Transmittal-Letter-CL-23-1011.pdf |
2023/10/11 |
|
| Transmittal-Letter-CL-23-1023.pdf |
2023/10/23 |
|
| Transmittal-Letter-CL-23-1221.pdf |
2023/12/21 |
|
| Transmittal-Letter-CL-23-1227-A.pdf |
2023/12/27 |
|
| Transmittal-Letter-CL-23-1227.pdf |
2023/12/27 |
|
| Transmittal-Letter-CL-24-0111.pdf |
2024/01/11 |
|
| Transmittal-Letter-CL-24-0112-1.pdf |
2024/01/12 |
|
| Transmittal-Letter-CL-24-0112.pdf |
2024/01/12 |
|
| Transmittal-Letter-CL-24-0131-A-AMENDED.pdf |
2024/01/31 |
|
| Transmittal-Letter-CL-24-0209.pdf |
2024/02/09 |
|
| Transmittal-Letter-CL-24-0213.pdf |
2024/02/13 |
|
| Transmittal-Letter-CL-24-0304.pdf |
2024/03/04 |
|
| Transmittal-Letter-CL-24-0312.pdf |
2024/03/12 |
|
| Transmittal-Letter-CL22-1031-A.pdf |
2022/10/31 |
|
| Transmittal-Letter-DSPR-ADENDUM.pdf |
|
|
| Transmittal-Letter-FMHP_PRV_23.80_142_S-1.pdf |
2023/01/01 |
|
| Transmittal-Letter-FMHP_PRV_23.80_142_S.pdf |
2023/01/01 |
|
| Transmittal-Letter-Informative-Letter-and-Reminder-Avoid-Interruptions-in-Cancer-Treatments.pdf |
|
|
| Transmittal-Letter-NC-22-01212-1.pdf |
2022/01/21 |
|
| Transmittal-Letter-NC-22-01212-2.pdf |
2022/01/21 |
|
| Transmittal-Letter-NC-22-0202-C.pdf |
2022/02/02 |
|
| Transmittal-Letter-NC-22-0202-D.pdf |
2022/02/02 |
|
| Transmittal-Letter-NC-22-0202-Ing.pdf |
2022/02/02 |
|
| Transmittal-Letter-NC-22-0330-A.pdf |
2022/03/30 |
|
| Transmittal-Letter-NC-22-0706-1-Normative-Letter-22-0706-1.pdf |
2022/07/06 |
|
| Transmittal-Letter-NC-22-0706-A.pdf |
2022/07/06 |
|
| Transmittal-Letter-NC-22-0706-Normative-Letter-22-0706.pdf |
2022/07/06 |
|
| Transmittal-Letter-NC-22-0803-Normative-Letter-22-0803.pdf |
2022/08/03 |
|
| Transmittal-Letter-NC-22-0907.pdf |
2022/09/07 |
|
| Transmittal-Letter-NC-22-0909.pdf |
2022/09/09 |
|
| Transmittal-Letter-NC-22-0916-A.pdf |
2022/09/16 |
|
| Transmittal-Letter-NC-22-1021-1.pdf |
2022/10/21 |
|
| Transmittal-Letter-NC-22-1101.pdf |
2022/11/01 |
|
| Transmittal-Letter-NC-22-1104.pdf |
2022/11/04 |
|
| Transmittal-Letter-NC-22-1227.pdf |
2022/12/27 |
|
| Transmittal-Letter-NC-23-0117-03 (1).pdf |
2023/01/17 |
|
| Transmittal-Letter-NC-23-0117-03.pdf |
2023/01/17 |
|
| Transmittal-Letter-NC-23-0117-2.pdf |
2023/01/17 |
|
| Transmittal-Letter-NC-23-0117.pdf |
2023/01/17 |
|
| Transmittal-Letter-NC-23-0126.pdf |
2023/01/26 |
|
| Transmittal-Letter-NC-23-0206.pdf |
2023/02/06 |
|
| Transmittal-Letter-NC-23-0223-REMINDER.pdf |
2023/02/23 |
|
| Transmittal-Letter-NC-23-0223.pdf |
2023/02/23 |
|
| Transmittal-Letter-NC-23-0403-1.pdf |
2023/04/03 |
|
| Transmittal-Letter-NC-23-0410.pdf |
2023/04/10 |
|
| Transmittal-Letter-NC-23-0517.pdf |
2023/05/17 |
|
| Transmittal-Letter-NC-23-0609.pdf |
2023/06/09 |
|
| Transmittal-Letter-NC-23-0613-1.pdf |
2023/06/13 |
|
| Transmittal-Letter-NC-23-0613.pdf |
2023/06/13 |
|
| Transmittal-Letter-NC-23-0621.pdf |
2023/06/21 |
|
| Transmittal-Letter-NC-23-0713.pdf |
2023/07/13 |
|
| Transmittal-Letter-NC-23-0728.pdf |
2023/07/28 |
|
| Transmittal-Letter-NC-23-0808-1.pdf |
2023/08/08 |
|
| Transmittal-Letter-NC-23-0808.pdf |
2023/08/08 |
|
| Transmittal-Letter-NC-23-0809.pdf |
2023/08/09 |
|
| Transmittal-Letter-NC-23-0907.pdf |
2023/09/07 |
|
| Transmittal-Letter-NC-23-1005-1-1.pdf |
2023/10/05 |
|
| Transmittal-Letter-NC-23-1005-Amended.pdf |
2023/10/05 |
|
| Transmittal-Letter-NC-23-1010-1-Adendum.pdf |
2023/10/10 |
|
| Transmittal-Letter-NC-23-1010-1.pdf |
2023/10/10 |
|
| Transmittal-Letter-NC-23-1010.pdf |
2023/10/10 |
|
| Transmittal-Letter-NC-23-1011.pdf |
2023/10/11 |
|
| Transmittal-Letter-NC-23-1215-1.pdf |
2023/12/15 |
|
| Transmittal-Letter-NC-23-1215.pdf |
2023/12/15 |
|
| Transmittal-Letter-NC19-0417-A.pdf |
2019/04/17 |
|
| Transmittal-Letter-NC23-0214.pdf |
2023/02/14 |
|
| Transmittal-Letter-NL-22-0202-F.pdf |
2022/02/02 |
|
| Transmittal-Letter-NL-23-0427.pdf |
2023/04/27 |
|
| Transmittal-Letter-NL-23-0608.pdf |
2023/06/08 |
|
| Transmittal-Letter-NL-23-0609.pdf |
2023/06/09 |
|
| Transmittal-Letter-NL-24-0112-A.pdf |
2024/01/12 |
|
| Transmittal-Letter-NL-24-0112.pdf |
2024/01/12 |
|
| Transmittal-Letter-NL-24-0216.pdf |
2024/02/16 |
|
| Transmittal-Letter-NL-24-0227.pdf |
2024/02/27 |
|
| Transmittal-Letter-O.A.-No.-2022-539.pdf |
2022/01/01 |
|
| Transmittal-Letter-O.A.-No.-2022-544.pdf |
2022/01/01 |
|
| Transmittal-Letter-OA-2023-583.pdf |
2023/01/01 |
|
| Transmittal-Letter-OA-2024-585.pdf |
2024/01/01 |
|
| Transmittal-Letter-OA-22-0915-Hurricane-Fiona.pdf |
2022/09/15 |
|
| Transmittal-Letter-OA-582.pdf |
|
|
| Transmittal-Letter-OE-2021-048.pdf |
2021/04/01 |
|
| Transmittal-Letter-PolicyASES-OC-2023-P003.pdf |
2023/01/01 |
|
| Transmittal-Letter.pdf |
|
|
| Transmittal-LetterIng.pdf |
|
|
| TransmittalLetterNormative24-0206NonRiskPayment.pdf |
2024/02/06 |
|
| Trasmittal-Letter-Circular-Letter-2022-0406-1-Mobile-Application-Development-Vital-Plan-.pdf |
2022/04/06 |
|
| Vital-Vaccination-Center.pdf |
|
|
| EPSDT Flyer_Early and Periodic Screening Diagnostic and Treatment VE 2024.pdf |
|
|
| Fall Prevention_VE 2024.pdf |
|
|
| FMHP_PRV_24.80_18_E_Provider Guidelines 2024_English_Approved_02062024.pdf |
2024/06/27 |
|
| Transmittal Letter NL-24-0719.pdf |
2024/08/08 |
|
| Transmittal Letter DSPR_AO No. 594.pdf |
2024/08/08 |
|
| Transmittal Letter NL-24-0609 Amended B.pdf |
2024/08/08 |
|
| ASES_Transmittal Letter NL-24-0808.pdf |
2024/08/13 |
|
| ASES_Transmittal Letter NL-24-0812.pdf |
2024/08/13 |
|
| DSPR_Transmittal Letter - FQHCs.pdf |
2024/08/13 |
|
| Fall Prevention_VE 2024.pdf |
|
|
| Transmittal Letter NL-24-0830 |
2024/09/05 |
|
| Transmittal Letter NL-24-0830-1 |
2024/09/05 |
|
| Transmittal Letter NL-24-0830-3 |
2024/09/06 |
|
| Transmittal Letter NL-24-0830-3 |
2024/09/06 |
|
| Transmittal Letter NL-24-0828-2 |
2024/09/06 |
|
| Transmittal Letter NL-24-00621-C Adendum |
2024/09/09 |
|
| Transmittal Letter NL-24-0828-1 Policy ASES-OC-2024 P003 |
2024/09/09 |
|
| Transmittal Letter NL-24-0830-4 |
2024/09/09 |
|
| Transmittal Letter NL-24-0808-A |
2024/09/09 |
|
| DSPR_Transmittal Letter CL-2024-006.pdf |
2024/09/12 |
|
| Transmittal Letter AO-2024-590 |
2024/09/13 |
|
| Transmittal Letter AO-24-589-A Amended |
2024/09/13 |
|
| Transmittal Letter CL-24-0911 |
2024/09/13 |
|
| Transmittal Letter CN 24-0911 |
2024/09/16 |
|
| Transmittal Letter NL-24-0829 |
2024/09/18 |
|
| Providers Directory September |
2024/09/20 |
|
| Transmittal Letter NL-24-0924 |
2024/09/30 |
|
| Transmittal Letter NL-24-0920 |
2024/09/30 |
|
| Transmittal Letter AO No. 596 |
2024/10/08 |
|
| Transmittal Letter NL-24-1004 |
2024/10/08 |
|
| Transmittal Letter CN 24-1016-1 - Changes to Preferred Drug List (PDL) |
2024/10/21 |
|
| Transmittal Letter NL 24-1016 - Preferred Drug List Changes PDL |
2024/10/21 |
|
| Transmittal Letter NL-241004-A Adendum |
2024/10/29 |
|
| Transmittal Letter AO-597 DSPR |
2024/10/31 |
|
| Transmittal Letter CL-24-1028 |
2024/10/31 |
|
| Transmittal Letter CL-24-1030 |
2024/10/31 |
|
| Transmittal Letter CL - 24-1104 |
2024/11/07 |
|
| Informative Letter PIP Placement Improvement Screening - PHQ 9 GAD7 DAST |
2024/11/07 |
|
| Transmittal Letter DSPR-AO 597-A ADENDUM |
2024/11/15 |
|
| Transmittal Letter Communication DSPR |
2024/11/25 |
|
| Transmittal Letter NL-2024-1122 |
2024/11/27 |
|
| Transmittal Letter Erratum NL-24-1203 |
2024/12/11 |
|
| Transmittal Letter NL-24-1217 |
2024/12/23 |
|
| Transmittal Letter AO-589-C |
2025/01/03 |
|
| Transmittal Letter NL-24-1220 |
2025/01/03 |
|
| Transmittal Letter NL-24-1227 |
2025/01/03 |
|